laurabbook@gmail.com

*January 2024* In Part One of a two-part podcast on oligometastatic lung cancer, host Dr. Narjust Florez interviews Dr. Fatima Wilder about how local therapies, such as radiation, cryoablation, and surgery, impact the treatment of this complex form of lung cancer. In Part Two of this Lung Cancer Considered podcast…

*January 2024* Note: This article discusses the analysis of circulating tumor DNA (ctDNA) in the context of osimertinib treatment for non-small cell lung cancer (NSCLC), specifically focusing on resistance mechanisms. It highlights the complexity of resistance mechanisms associated with osimertinib treatment in NSCLC and the importance of understanding genetic changes for effective management.…

*January 2024* A premarket approval (PMA) application regarding the addition of tumor-treating fields (TTFields) to standard-of-care (SOC) therapies in patients with non­–small cell lung cancer (NSCLC) after disease progression on or following platinum-based treatment has been accepted for filing by the FDA.1 The PMA was supported by data from the phase…

*January 2024* Treatment with patritumab deruxtecan (HER3-DXd) in patients with locally advanced or metastatic, EGFR-mutated non–small cell lung cancer (NSCLC) resulted in clinically meaningful efficacy and long-lasting responses in those who progressed following EGFR tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy, according to data from the phase 2 HERTHENA-Lung01 study…

*January 2024* While the standard-of-care recommendations can vary depending on the individual patient, EGFR tyrosine kinase inhibitors (TKIs) like osimertinib (Tagrisso) have played a pivotal role in the treatment of patients with EGFR-mutated lung cancer in recent years. Osimertinib tends to be the preferred first-line treatment for most patients who harbor…

*December 2023* Introduction NSCLC transformation to SCLC has been best characterized with EGFR-mutant NSCLC, with emerging case reports seen in ALK, RET, and KRAS-altered NSCLC. Previous reports showed transformed SCLC from EGFR-mutant NSCLC portends very poor prognosis and lack effective treatment. Genomic analyses showed TP53 and RB1 loss of function increase the risk of SCLC transformation. Little has been…

*December 2023* The FDA has accepted and granted priority review to the biologics license application (BLA) seeking the approval of the HER3-directed antibody-drug conjugate (ADC) patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) who previously received at least 2…